38 related articles for article (PubMed ID: 12200354)
1. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas M; Knopinska-Posluszny W; Piątkowska-Jakubas B; García-Álvarez F; Díez MEA; Caballero M; Martínez-Cuadrón D; Aguiar E; González-Campos J; Garrido A; Algarra L; Salamero O; de la Serna J; Sayas MJ; Perez-Encinas MM; Vives S; Vidriales B; Labrador J; Prado AI; Celebrin L; Mayer J; Brioso J; de Laiglesia A; Bergua JM; Amigo ML; Rodriguez-Medina C; Polo M; Pluta A; Cichocka E; Skarupski M; Sanz MA; Wierzbowska A; Montesinos P
Ann Hematol; 2024 Feb; 103(2):451-461. PubMed ID: 38110588
[TBL] [Abstract][Full Text] [Related]
2. [Clinical effect of the SCMC APL-2010 regimen in treatment of acute promyelocytic leukemia in children: an analysis of 44 cases].
Wang Z; Shen SH; Tang YJ; Xue HL; Hu WT; Pan C; Tang JY; Gu LJ; Chen J
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Nov; 21(11):1073-1078. PubMed ID: 31753087
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre.
Karim F; Shaikh U; Adil SN; Khurshid M
Singapore Med J; 2014 Aug; 55(8):443-7. PubMed ID: 25189308
[TBL] [Abstract][Full Text] [Related]
4. Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California.
Abrahão R; Ribeiro RC; Medeiros BC; Keogh RH; Keegan TH
Cancer; 2015 Nov; 121(22):3990-7. PubMed ID: 26264598
[TBL] [Abstract][Full Text] [Related]
5. Global characteristics of childhood acute promyelocytic leukemia.
Zhang L; Samad A; Pombo-de-Oliveira MS; Scelo G; Smith MT; Feusner J; Wiemels JL; Metayer C
Blood Rev; 2015 Mar; 29(2):101-25. PubMed ID: 25445717
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
[TBL] [Abstract][Full Text] [Related]
7. Adult acute myeloid leukaemia.
Smith M; Barnett M; Bassan R; Gatta G; Tondini C; Kern W
Crit Rev Oncol Hematol; 2004 Jun; 50(3):197-222. PubMed ID: 15182826
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
9. Transcription therapy for acute promyelocytic leukaemia.
Douer D
Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
[TBL] [Abstract][Full Text] [Related]
10. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.
Pulsoni A; Pagano L; Lo Coco F; Avvisati G; Mele L; Di Bona E; Invernizzi R; Leoni F; Marmont F; Mele A; Melillo L; Nosari AM; Pogliani EM; Vignetti M; Visani G; Zagonel V; Leone G; Mandelli F
Blood; 2002 Sep; 100(6):1972-6. PubMed ID: 12200354
[TBL] [Abstract][Full Text] [Related]
11. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
13. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.
Mandelli F; Latagliata R; Avvisati G; Fazi P; Rodeghiero F; Leoni F; Gobbi M; Nobile F; Gallo E; Fanin R; Amadori S; Vignetti M; Fioritoni G; Ferrara F; Peta A; Giustolisi R; Broccia G; Petti MC; Lo-Coco F;
Leukemia; 2003 Jun; 17(6):1085-90. PubMed ID: 12764372
[TBL] [Abstract][Full Text] [Related]
14. Long-term survey of outcome in acute promyelocytic leukemia.
Hu J; Shen Z; Sun H; Wu W; Li X; Sun G; Wang Z
Chin Med J (Engl); 2000 Feb; 113(2):107-10. PubMed ID: 11775530
[TBL] [Abstract][Full Text] [Related]
15. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
